Combined mesenchymal stem cells and telitacicept therapy for Evans syndrome refractory to various immunosuppressive: a case report
This case suggests that combined therapy with telitacicept and MSCs may represent an effective therapeutic option for patients with refractory ES. The complementary immunosuppressive mechanisms of BAFF/APRIL blockade and MSC-mediated immune regulation may provide synergistic disease control and warrant further investigation in larger clinical studies.
Authors
- Huan Vinh Dong (ORCID: https://orcid.org/0000-0002-6370-1811)
- Zhibo Han
- Wei Liu
- Lei Zhang
- Xiaolei Pei
- Feng Xue
- Renchi Yang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tianjin Institute of Pharmaceutical Research (China) (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.rpth.2026.103393
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00